TIDMDXRX

RNS Number : 4749L

Diaceutics PLC

13 September 2021

13 September 2021

Diaceutics PLC

("Diaceutics" or "the Company")

DXRX platform contract win

Diaceutics PLC (AIM: DXRX), the diagnostic commercialisation company, is pleased to announce that it has secured a contract with a global pharmaceutical company for the provision of technology enabled services, to be delivered via its DXRX platform. The contract value is in excess of $900,000, with the majority of revenue to be recognised in the current financial year, supporting the Company's growth targets and current year forecasts.

Diaceutics will collaborate with the client to support the launch of a diagnostic test alongside a new oncology drug. Both the diagnostic test and drug are new to the market and as such the diagnostic test will require adoption by laboratories globally in order for the drug to be prescribed by physicians. This initial contract will involve creating a Quality Assurance standard across 30 laboratories in ten countries to ensure that results and interpretation are consistent wherever the test is undertaken.

Peter Keeling, CEO and Founder of Diaceutics PLC, commented :

"We are very pleased to be supporting the commercialisation of this new oncology drug for our client. This drug has the potential to help many cancer patients when on the market and the work done now will mean more patients having access to this drug, earlier. Through the use of the DXRX platform, we anticipate the study to be completed swiftly, utilising our growing online lab network ."

Enquiries:

 
Diaceutics PLC 
Philip White, Chief Financial Officer           Via Alma PR 
 
Stifel Nicolaus Europe Limited (Nomad & Broker  Tel: +44 (0)20 7710 
 )                                               7600 
Ben Maddison 
Stewart Wallace 
Nick Adams 
 
Alma PR                                         Tel: +44(0)20 3405 
                                                 0205 
Caroline Forde                                  diaceutics@almapr.co.uk 
Robyn Fisher 
Kieran Breheny 
 Matthew Young 
 

About Diaceutics

At Diaceutics we believe that every patient should have access to the right treatment at the right time. We provide the world's leading pharmaceutical companies with an end-to-end solution for the launch of precision medicine diagnostics enabled by DXRX - The Diagnostic Network(R).

DXRX is the world's first diagnostic commercialisation platform for precision medicine, integrating multiple pipelines of real-world diagnostic testing data from a global network of laboratories.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

CNTLMMFTMTIBBFB

(END) Dow Jones Newswires

September 13, 2021 02:00 ET (06:00 GMT)

Diaceutics (LSE:DXRX)
Gráfica de Acción Histórica
De Feb 2024 a Mar 2024 Haga Click aquí para más Gráficas Diaceutics.
Diaceutics (LSE:DXRX)
Gráfica de Acción Histórica
De Mar 2023 a Mar 2024 Haga Click aquí para más Gráficas Diaceutics.